VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Share Price
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 428.6 USD | -0.31% |
|
+4.47% | +5.33% |
| 05-14 | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 | MT |
| 05-10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
| Sales 2024 * | 10.75B 854B | Sales 2025 * | 11.67B 927B | Capitalization | 111B 8,815B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.99B 317B | Net income 2025 * | 4.46B 355B | EV / Sales 2024 * | 9.02 x |
| Net cash position 2024 * | 13.97B 1,110B | Net cash position 2025 * | 19.01B 1,511B | EV / Sales 2025 * | 7.88 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
25.1
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | -0.31% | ||
| 1 week | +4.47% | ||
| Current month | +9.11% | ||
| 1 month | +8.08% | ||
| 3 months | +2.56% | ||
| 6 months | +15.85% | ||
| Current year | +5.33% |
1 week
416.03
430.52
1 month
391.01430.52
Current year
391.01448.40
1 year
320.01448.40
3 years
176.36448.40
5 years
165.23448.40
10 years
63.60448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 31/01/17 | |
Jeffrey Leiden
CHM | Chairman | 68 | 07/07/09 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 09/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 07/06/17 |
Jeffrey Leiden
CHM | Chairman | 68 | 07/07/09 |
Bruce Sachs
BRD | Director/Board Member | 64 | 31/12/97 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 428.6 | -0.31% | 934,432 |
| 13/05/24 | 429.9 | +1.69% | 939,753 |
| 10/05/24 | 422.8 | +0.90% | 1,064,604 |
| 09/05/24 | 419 | +0.04% | 676,185 |
| 08/05/24 | 418.8 | +2.09% | 1,651,673 |
Delayed Quote Nasdaq, May 14, 2024 at 09:00 pm
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
02:00pm
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
428.6
USD
Average target price
462.6
USD
Spread / Average Target
+7.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B | |
| +289.58% | 7.98B |
- Stock Market
- Equities
- VRTX Stock
